Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Conditioned CAR-T cells (cirCAR-T) for enhanced tumor immmunotherapy

Objectif

Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough immunotherapy for aggressive blood cancers. With >250 companies active in the field, >1,200 CAR- T variants in clinical development, and a market exceeding $5B, CAR-T therapies represent an expanding biomedical sector. However, despite response rates of up to 90%, long-term remissions remain limited (30–40%), and efficacy in solid tumors remains poor, highlighting a major unmet medical need. Improving CAR-T cell potency, persistence, and functionality thus remains a central challenge. My ERC project CIRCADYN uncovered a previously unrecognised mechanism in regulating immune responses and immunotherapy efficacy. Building on these findings, we developed a novel strategy, termed cirCAR-T, which enhances CAR-T cell performance without additional genetic modification. Preliminary data demonstrate up to a 10-fold increase in tumor cell killing and up to a 9-fold increase in antigen-driven CAR-T cell proliferation. This Proof-of-Concept project will de-risk the translational potential of cirCAR-T through three complementary objectives: (i) demonstrating functional benefits in more physiologically relevant solid tumor contexts and evaluating initial safety signals; (ii) establishing a knowledge-transfer strategy through expert consultation to clarify regulatory classification, intellectual-property options, freedom-to-operate considerations, and (iii) mapping the most efficient commercialization pathways. Together, these activities will determine the feasibility of developing cirCAR-T as a novel enabling technology to enhance CAR-T cell potency and persistence and support their expansion toward broader clinical applications, including solid tumors.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-POC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

UNIVERSITE DE GENEVE
Contribution nette de l'UE
€ 150 000,00
Adresse
RUE DU GENERAL DUFOUR 24
1211 Geneve
Suisse
Région
Schweiz/Suisse/Svizzera Région lémanique Genève
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée

Bénéficiaires (1)